BNP Paribas Financial Markets Acquires 8,656 Shares of AxoGen, Inc. (NASDAQ:AXGN)

BNP Paribas Financial Markets increased its stake in AxoGen, Inc. (NASDAQ:AXGN) by 238.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,284 shares of the medical equipment provider’s stock after buying an additional 8,656 shares during the quarter. BNP Paribas Financial Markets’ holdings in AxoGen were worth $172,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Quest Partners LLC boosted its stake in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC bought a new position in shares of AxoGen in the third quarter worth approximately $56,000. Koss Olinger Consulting LLC purchased a new stake in shares of AxoGen during the second quarter valued at approximately $75,000. Acadian Asset Management LLC purchased a new stake in shares of AxoGen during the second quarter valued at approximately $125,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of AxoGen during the third quarter valued at approximately $156,000. 80.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $15.00.

AxoGen Stock Performance

Shares of NASDAQ AXGN opened at $14.74 on Wednesday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average price is $13.83 and its 200-day moving average price is $11.56. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $15.90. The company has a market cap of $648.68 million, a PE ratio of -46.06 and a beta of 1.06.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.